What are PNPLA3 antibodies?
Anti-PNPLA3 antibodies are immunoglobulins that specifically recognize and bind PNPLA3, the gene encoding 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (also known as adiponutrin) in humans. In research applications, these antibodies are used to detect PNPLA3 in tissue samples, cell lysates, and cultured cells. PNPLA3 catalyzes coenzyme A-dependent acylation of lysophosphatidic acid to generate phosphatidic acid, an intermediate in the synthesis of triglycerides and glycerophospholipids. Because the I148M variant of PNPLA3 is strongly associated with hepatic fat accumulation, antibodies against it are central to nonalcoholic fatty liver disease research.
Catalog highlights and purchasing considerations
About the Biocompare PNPLA3 antibody catalog
The Biocompare antibody search tool lists anti-PNPLA3 antibodies from a range of suppliers, spanning unconjugated and fluorophore- or enzyme-conjugated formats. Listings may also appear under the alternate name adiponutrin. Western blot is the most common validated application among these listings, followed by immunohistochemistry and ELISA. Several PNPLA3 antibodies mentioned here have been cited across a range of hepatology research, including CRISPR prime editing models of the disease-associated I148M variant, I148M-driven reductions in hepatic triglyceride secretion linked to diastolic dysfunction, and development of a small-molecule PNPLA3 I148M degrader.
Considerations when choosing a PNPLA3 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.